Hunan Dajiaweikang Pharmaceutical Industry Co (301126) Fair Value & Analysis
Healthcare · CN · Market cap 1.9B CNY
Fair value as of: Jul 9, 2026
From 6 valuation models · updated today
Fair value updated Jul 9, 2026 — revised from ¥39.84 to ¥4.96 (−87.6%) since Jun 24, 2026. Share price −12.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥8.55 – ¥14.35 · fair‑value band ¥0.9920 – ¥9.17 · the ¥8.84 price screens above the ¥4.96 fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Hunan Dajiaweikang Pharmaceutical Industry Co (301126) currently trades at ¥8.84, while our model-based Fair Value estimate is ¥4.96 — implying the stock looks roughly 43.9% overvalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Hunan Dajiaweikang Pharmaceutical Industry Co generated revenue of 5.2B CNY at a net margin of -4.6%. Revenue grew 6.5% year over year. It earns a return on equity of -13.2%. Net debt stands at 2.4B CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥0.9920 (bear case) to ¥9.17 (bull case); at ¥8.84, the current price sits within that range. The share trades about 41% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 45% fair-value upside — at -44%, 301126 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd engages in the wholesale and retail of pharmaceuticals products in China. It provides raw materials, biological products, chemical drugs, Chinese herbal medicines, medical devices, and other products. The company also offers Chinese patent medicines in the form of granules, capsules, particles, tablets, slices, and pills; foods, such as beverages, drinks, and probiotic beverages; and cleansing and care products. In addition, it provides pharmaceutical logistics services; and operates reproductive hospitals. The company was formerly known as Hunan Tongjian Pharmacy CO., LTD and changed its name to Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd in August 2016. Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd was founded in 2002 and is headquartered in Changsha, China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hunan Dajiaweikang Pharmaceutical Industry Co reported revenue of ¥5.1B in FY2025 versus ¥2.6B in FY2021, a compound +18.7%/yr. Reported net income was −¥242M in FY2025.
Is 301126 fairly valued? → Check now
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIY | $5.33 | $7.09 | +33% |
| Alibaba Health Information Technology Limited ALBBY | $8.42 | $6.94 | -18% |
| Raia Drogasil S.A RADL3 | R$17.76 | R$14.97 | -16% |
| Yifeng Pharmacy Chain Co 603939 | ¥19.75 | ¥29.07 | +47% |
| Clicks Group CLCGY | $28.55 | $41.54 | +45% |
| Sugi Holdings SGIPF | $16.29 | $29.89 | +83% |
| Corporativo Fragua, S.A. CGSBF | $29.66 | $29.34 | -1% |
| DaShenLin Pharmaceutical Group 603233 | ¥15.87 | ¥23.86 | +50% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.74 | ¥10.57 | -10% |
| Redcare Pharmacy NV SHPPF | $64.80 | $143.56 | +122% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hunan Dajiaweikang Pharmaceutical Industry Co (301126) undervalued?
What is the fair value of 301126?
What is the quality score of 301126?
What is the revenue of Hunan Dajiaweikang Pharmaceutical Industry Co (301126)?
What is the net profit margin of 301126?
Does Hunan Dajiaweikang Pharmaceutical Industry Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.